Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Silver

Showing results (171-180 of 232) with videos related to

Pageof 24
Sort By:
Blood|December 15, 2005
Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alphaAmy V Jones, Richard T Silver, Katherine Waghorn, et al.
Medical and Pediatric Oncology|January 1, 1979
A comparative trial of daunorubicin, cytosine arabinoside, and thioguanine, and a combination of the three agents for the treatment of acute myelocytic leukemiaP H Wiernik, O J Glidewell, H C Hoagland, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1997
Value of molecular monitoring during the treatment of chronic myeloid leukemia: a Cancer and Leukemia Group B studyW Stock, C A Westbrook, B Peterson, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2016
Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful EngraftmentUsama Gergis, Emil Kuriakose, Tsiporah Shore, et al.
Medical and Pediatric Oncology|January 1, 1975
The use of low-dose prednisone and melphalan in the treatment of poor-risk patients with multiple myelomaJ Cuttner, L R Wasserman, G Martz, et al.
Haematologica|February 9, 2010
Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinibNeil P Shah, Dong-Wook Kim, Hagop Kantarjian, et al.
Cancer|November 1, 1982
Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experienceG G Cornwell, T F Pajak, S Kochwa, et al.
International Journal of Oncology|June 18, 2004
Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B studySherif S Farag, Amy S Ruppert, Krzysztof Mrózek, et al.
Methods of Information in Medicine|April 17, 2025
Automated Information Extraction from Unstructured Hematopathology Reports to Support Response Assessment in Myeloproliferative NeoplasmsSpencer Krichevsky, Evan T Sholle, Prakash M Adekkanattu, et al.
Health Psychology : Official Journal of the Division of Health Psychology, American Psychological Association|February 24, 2001
Persistent symptoms among survivors of Hodgkin's disease: an explanatory model based on classical conditioningC L Cameron, D Cella, J E Herndon, et al.
Pageof 24

Showing results (171-180 of 232) with videos related to

Sort By:
Pageof 24
Blood|December 15, 2005
Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alphaAmy V Jones, Richard T Silver, Katherine Waghorn, et al.
Medical and Pediatric Oncology|January 1, 1979
A comparative trial of daunorubicin, cytosine arabinoside, and thioguanine, and a combination of the three agents for the treatment of acute myelocytic leukemiaP H Wiernik, O J Glidewell, H C Hoagland, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1997
Value of molecular monitoring during the treatment of chronic myeloid leukemia: a Cancer and Leukemia Group B studyW Stock, C A Westbrook, B Peterson, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2016
Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful EngraftmentUsama Gergis, Emil Kuriakose, Tsiporah Shore, et al.
Medical and Pediatric Oncology|January 1, 1975
The use of low-dose prednisone and melphalan in the treatment of poor-risk patients with multiple myelomaJ Cuttner, L R Wasserman, G Martz, et al.
Haematologica|February 9, 2010
Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinibNeil P Shah, Dong-Wook Kim, Hagop Kantarjian, et al.
Cancer|November 1, 1982
Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experienceG G Cornwell, T F Pajak, S Kochwa, et al.
International Journal of Oncology|June 18, 2004
Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B studySherif S Farag, Amy S Ruppert, Krzysztof Mrózek, et al.
Methods of Information in Medicine|April 17, 2025
Automated Information Extraction from Unstructured Hematopathology Reports to Support Response Assessment in Myeloproliferative NeoplasmsSpencer Krichevsky, Evan T Sholle, Prakash M Adekkanattu, et al.
Health Psychology : Official Journal of the Division of Health Psychology, American Psychological Association|February 24, 2001
Persistent symptoms among survivors of Hodgkin's disease: an explanatory model based on classical conditioningC L Cameron, D Cella, J E Herndon, et al.
Pageof 24